April 9, 2024 – Page 4 – Goldea Capital

Total number of shares and voting rights at March 31, 2024

Written by Customer Service on April 9, 2024. Posted in Public Companies.

9 April 2024 Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years. Date Number of shares Number of treasury shares without voting rights Theoretical number of voting rights [1] Number of voting rights exercisable 01/31/2024 2, 660, 056,599 2, 014,145 3, 154, 643,135 3 152, 628,990 02/29/2024 2, 660, 056,599 1, 874,145 3, 154, 554,054 3, 152, 679,909 03/31/2024 2, 660, 056,599 1, 770,145 3,...

COMBINED SHAREHOLDERS’ MEETING

Written by Customer Service on April 9, 2024. Posted in Public Companies.

COMBINED SHAREHOLDERS’ MEETINGOF APRIL 30, 2024 Rexel informs its shareholders that its Combined Shareholders’ Meeting (ordinary and extraordinary) will be held on April 30, 2024 at 10:30 a.m. at Châteauform’ City George V, 28, avenue George V, 75008 Paris. The prior notice of meeting (“avis de réunion”) was published in the Bulletin des annonces légales obligatoires (BALO), dated Friday, March 22, 2024 (www.journal‐officiel.gouv.fr/balo), bulletin No. 36 (reference number 2400595). It contains the detailed agenda for the meeting and the draft resolutions and describes how shareholders can take part in and vote at the meeting. The convening notice for shareholders (“avis de convocation”) will be published in the Bulletin des annonces légales obligatoires (BALO) of Friday, April 12, 2024 and in Journal Spécial des Sociétés Françaises par...

Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024

Written by Customer Service on April 9, 2024. Posted in Public Companies.

Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C – ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com Date Total of shares composing the share capital Total of brut (1) voting rights Total of net (2) voting rights December 31, 2023 6 075 105 6 226 982 6 226 733 January 31, 2024 6 075 105 6 227 002 6 226 753 February 29, 2024 6 075 105 6 226 951 6 226 702 March 29, 2024 6 075 105 6 226 938 6 226 689 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including...

Hermès International: Shares and voting rights as of 31 March 2024

Written by Customer Service on April 9, 2024. Posted in Public Companies.

RELEASE Paris, April 9, 2024 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITAL In accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from those previously published. Date Total number of shares Total number of theoretical voting rights (including treasury stock) Total number of effective voting rights (exercisable at shareholders’ meetings) Publications 31 March 2024 105 569 412 179 116 106 178 279 224 9 April 2024 29 February 2024 105 569 412 179 126 463 178 289...

EUROAPI streamlines its Executive Committee to improve focus and efficiency

Written by Customer Service on April 9, 2024. Posted in Public Companies.

Press Release Paris – April 9, 2024 – EUROAPI today announces a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. This organizational adjustment is part of the transformation of EUROAPI into an innovative API supplier and CDMO with a unique, high-quality and customized product offering. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour, Chief Financial Officer Thierry Durand, Chief R&D Officer Ute Herzog, Chief Human Resources Officer Cécile Maupas, Chief CDMO Officer Guillaume Rosso, Chief Commercial Officer David Seignolle, Chief Operating Officer “Setting...

Beamr to enable real-time video streaming over 5G with NVIDIA Holoscan for Media

Written by Customer Service on April 9, 2024. Posted in Public Companies.

Herzliya Israel, April 09, 2024 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today announced that it plans to demonstrate a real-time video optimization application with the NVIDIA Holoscan for Media, a software-defined platform that enables developers to easily build live media applications, at NAB Show 2024, a premier event for the broadcasting, streaming and media industry in Las Vegas, Nevada, on April 13-17, 2024. 5G increased bandwidth is not sufficient to support the always-growing demand for real-time video streaming required for live event transmission and other use cases across a wide set of industries, including edge computing, IoT, and building robots, drones, autonomous vehicles and automated cameras. With these industries’ increasing use of ultra-high-definition...

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Written by Customer Service on April 9, 2024. Posted in Public Companies.

MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor associated antigen, which is overexpressed by immunologically “cold” tumors with high unmet needs in pancreatic, prostate, ovarian, breast and brain cancer affecting over two million patients every year TORONTO and HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data on MDNA113, the Company’s novel...

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Written by Customer Service on April 9, 2024. Posted in Public Companies.

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study. Seven women...

Shopping centres controlled by Akropolis Group had over 44 million visitors last year, the tenants’ turnover reached almost EUR 1.2 billion, over 100 new and revamped shops opened, leading to growth of the Group’s revenue

Written by Customer Service on April 9, 2024. Posted in Public Companies.

Five shopping and entertainment centres controlled by Akropolis Group in Lithuania and Latvia had over 44 million visitors in 2023, which is 7% more than in 2022. Bigger visitor footfall contributed to the growth of shopping centres tenants’ turnover, which was almost EUR 1.2 billion last year – 7% more than in 2022 (EUR 1.1 billion). “2023 was the first year when the shopping centres were no longer subject to any COVID-19 related restrictions, which had a positive effect on the performance: Akropolis shopping and entertainment had more visitors and the tenants saw the growth in their business volumes. In the five shopping centres controlled by Akropolis Group, we welcomed more than 44 million visitors last year and the tenants’ turnover reached almost EUR 1.2 billion. The results were positively influenced by renovation of the shopping...

CV Holdings, Inc. Update and Financial Statements for Year Ended December 31, 2023

Written by Customer Service on April 9, 2024. Posted in Earnings Releases And Operating Results.

NEWPORT BEACH, Calif., April 09, 2024 (GLOBE NEWSWIRE) — CV Holdings, Inc. (OTC Pink Limited: CVHL) (the “Company”) today reported a net loss for the year ended December 31, 2023 of $(15,959,005) or $(0.25) per common share with weighted average common shares of 64,413,784 issued and outstanding during 2023. Taking into account the December 31, 2023 balance of 64,413,784 common shares issued and outstanding and 4,148,532 common shares issuable upon exercise of warrants outstanding, the net loss was $(0.23) per diluted common share based on 68,562,316 common shares outstanding on a fully-diluted basis. The net loss for the year ended December 31, 2023 was primarily due to interest expense on preferred equity of $12,860,976 as well as the Company’s provision for loan losses of $7,423,794 and interest expense on debt of $7,986,605....

Day: April 9, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice